VivoSeq
Oncology

Thyroid Cancer

185

Pipeline Programs↗

76

Active Trials↗

57

Companies Involved↗

Thyroid Cancer is a highly competitive landscape with 185 programs across 57 companies. The most active players are AffyImmune Therapeutics, Inc., Celldex Therapeutics, Calithera Biosciences, Inc. 17 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

81/100

Pipeline Velocity

34/100

Mech. Concentration

4/100

Completion Rate

76/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

AffyImmune Therapeutics, Inc.

1 program

Phase 1C

Celldex Therapeutics

1 program

Phase 1C

Calithera Biosciences, Inc

1 program

Phase 1Amgen logo

Amgen

3 programs

Phase 2E

Eastern Cooperative Oncology Group

3 programs

Phase 2Takeda logo

Takeda

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical18

Cabozantinib

Bristol-Myers Squibb

Levothyroxine Sodium

Mylan Pharmaceuticals Inc

177lu-DOTA-EB-TATE

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Ferumoxytol

Azurity Pharmaceuticals

Carbon Nanoparticles

Peking University Cancer Hospital & Institute

Phase 124

Bexarotene

Bausch Health Americas, Inc.

Imatinib

Novartis

Sapanisertib

Calithera Biosciences, Inc

Durvalumab

AstraZeneca

Tremelimumab

AstraZeneca

Phase 2114

Abemaciclib

Eli Lilly

Tipifarnib

Kura Oncology, Inc.

Camrelizumab

Sun Yat-sen University

Vemurafenib

Conrado Roberto Hoffmann Filho

Atezolizumab

Roche

Phase 312

Metformin

EMD Serono

Sorafenib

Bayer

Selumetinib

AstraZeneca

Systematic RAI-Treatment

Centre Francois Baclesse

XL184

Exelixis

Approved17

Larotrectinib

Bayer

Selpercatinib

Eli Lilly

Pralsetinib

Rigel Pharmaceuticals

Entrectinib

Roche

Gemcitabine

Johnson & Johnson

Analysis

Modality Breakdown

85%

Small molecule

175 of 207 classified programs — the dominant modality here.

15%ALL OTHERSMonoclonal antibody2010%Protein / enzyme63%Radiopharmaceutical31%Peptide2<1%Cell therapy1<1%

Small molecule leads; the ring shows all 207 classified programs, each share of the total. Modality classified for 100% of 211 pipeline programs.

Analysis

Trial Status

249

clinical trials

Completed109 · 44%
Recruiting37 · 15%
Active, not recruiting29 · 12%
Unknown status27 · 11%
Terminated22 · 9%
Withdrawn11 · 4%
Other14 · 6%

Clinical Trials

Trial Activity

249 trials

Sacituzumab govitEcan in THYroid Cancers
Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT06235216·42 enrolled
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Recruiting·FFudan University·Phase 4·NCT06195228·800 enrolled
XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT06902376·12 enrolled
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Recruiting·SSaint Petersburg State University, Russia·Phase 2·NCT06362694·10 enrolled
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
Recruiting·BBeijing Scitech-Mq Pharmaceuticals Limited·Phase 2·NCT06359847·60 enrolled
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Recruiting·—·Phase 2·NCT06458036·13 enrolled
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Recruiting·WWashington University School of Medicine·Phase 2·NCT07092514·34 enrolled
Safety and Efficacy of Recombinant Human Thyroid Stimulating Hormone for Adjuvant Diagnosis in Patients With Locally Advanced/Metastatic Differentiated Thyroid Cancer
Recruiting·NNanjing First Hospital, Nanjing Medical University·N/A·NCT06431620·15 enrolled
A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer.
Recruiting·SSecond Affiliated Hospital of Xi'an Jiaotong University·Phase 3·NCT06791005·400 enrolled
RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer
Recruiting·FFudan University·N/A·NCT06530316·48 enrolled
Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer
Recruiting·PPeking Union Medical College Hospital·Phase 1·NCT06898437·20 enrolled
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04589624·42 enrolled
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
Recruiting·VVanderbilt University Medical Center·Phase 3·NCT05999630·100 enrolled
Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Recruiting·FFudan University·Phase 2·NCT06970353·40 enrolled
Page 1 of 17

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)